

CARDIOVASCULAR CARE


Cardiovascular Care

SOLUTIONS

From routine lipid evaluations to complex genetic studies, LabCorp provides an extensive menu of cardiovascular disease (CVD) testing to support the spectrum of clinical scenarios that you face each day.

LabCorp's medical and scientific professionals have constructed a comprehensive test menu to address the complexities of cardiovascular care, and our ancillary tools and services help assimilate these tests into your practice's workflow.





Beyond a comprehensive test menu, LabCorp offers ancillary tools and services to help enhance your practice, organization, quality measures, health information technology, and patient care.

SERVICES AND TOOLS

LabCorp Link™ for test orders, results delivery, analytics, and trending

Cardiovascular Report for at-risk patients

Cardiovascular-specific Test Request Form for efficient test ordering

SERVICES AND TOOLS

A Result Report Like No Other

Available in PDF or HL7 format, the cardiovascular report presents a patient-specific, guideline-based analysis of lipid test results in light of cardiovascular risk factors.

A patient friendly version of the report is available for patient consulting. Reports may also include Current Laboratory Results, with visual cues relative to reference intervals, and Flow Sheets, which trend results over eight future dates of service.

Generate the report for all patients when ordering a lipid panel, **NMR LipoProfile®** test, or either **Lipid Cascade** option by completing the Cardiovascular Report Physician Request and Acknowledgement form. Alternatively, order test **910385** in addition to a lipid panel, **NMR LipoProfile** test, or either **Lipid Cascade** option to generate the color graphic PDF report as needed.

- Provides actionable information in support of clinical decision-making.
- Can be used to help educate and counsel patients.

Sample Patient 1
 DATE OF BIRTH: 08/03/1960
 GENDER: M
 DATE OF SERVICE: 04/14/2014
 PHYSICIAN: Sample Physician

Cardiovascular Risk Assessment
 Analysis & Treatment Suggestions

Patient Risk Assessment
 Current available clinical information suggests the patient's risk is at least HIGH. Your patient appears to have one CHD risk equivalent (diabetes). One additional major risk factor is present (age over 45).

Patient Risk Category
 Select one patient risk category based upon medical history and clinical judgment. Additional risk factors such as personal or family history of premature CHD, smoking, and hypertension modify a patient's goals of therapy. In CVD prevention, the intensity of therapy should be adjusted to the level of patient risk. MODERATE intensity statin therapy generally results in an average LDL-C reduction of 30% to less than 50% from the untreated baseline. Examples include (daily doses): atorvastatin 40-80 mg and rosuvastatin 20 mg. HIGH intensity statin therapy generally results in an average LDL-C reduction of 50% or more from the untreated baseline. Examples include (daily doses): atorvastatin 40-80 mg and rosuvastatin 20 mg.

ANALYTE / RESULT	Patient Risk Category (select one)		
	LOW	INTERMEDIATE	HIGH
LDL-C 71 mg/dL	180	100-130	70-100
non-HDL 100 mg/dL	150	100-130	70-100
LDL-P 1035 nmol/L	1500	1000-1300	500-1000

Lipid Assessment
 LDL-C is optimal, was 66 and now is 71 mg/dL. Non-HDL Cholesterol is optimal, was 93 and now is 100 mg/dL. LDL-P is acceptable, 1035 nmol/L. Please refer to assessment and treatment suggestions under high risk category.

Treatment Suggestions

Disease Risk Category
 Select one disease risk category based upon your risk factors and clinical judgment.

Intermediate **High**

Lipid Cascade
 Trending results for LDL-C, non-HDL, and LDL-P over eight future dates of service.

LabCorp
 Mitchell S. Lake, PhD
 Laboratory Director
 CLIA# 14C0987314
 800-338-4333 Telephone
 866-361-7939 Facsimile
 www.labcorp.com
 Version: 6.13.2.19
 Printed: 04/16/2014
 Page: 3 of 3

AVAILABLE TESTS

Lipids and Lipoproteins


016873	Apolipoprotein A-1
216010	Apolipoprotein Assessment
167015	Apolipoprotein B
884247	NMR LipoProfile®
361946	Lipid Cascade With Reflex to Lipoprotein Particle Assessment by NMR
363676	Lipid Cascade With Reflex to Apolipoprotein B
303756	Lipid Panel
343925	Lipid Profile With Non-HDL Cholesterol
368600	Familial Hypercholesterolemia (FH) Screen
235036	Lipoprotein Phenotyping Profile
120295	Low-density Lipoprotein Cholesterol (Direct)
818542	HDL-P, Total*
120188	Lipoprotein(a)
235010	Lipid Panel With LDL:HDL Ratio
221010	Lipid Panel With Total Cholesterol:HDL Ratio

* This test was developed and its performance characteristics were determined by LipoScience. It has not been cleared or approved by the Food and Drug Administration.

The Lipid Cascade “Smart” Testing Approach

Requiring a single blood draw, LabCorp’s Lipid Cascade provides convenient, step-wise testing for patient management.

Note: LDL values greater than 130 mg/dL do not reflex.



*Additional charge

THE CLINICAL CHALLENGE

Cardiovascular disease risk management in at-risk patient populations

- The role of high levels of low-density lipoprotein (LDL) particles in the development of cardiovascular disease (CVD) is well established.¹
- Elevated LDL drives entry of these atherogenic particles into the arterial wall, accelerating development of CVD.¹ The longer there is exposure to elevated LDL, the greater the risk for clinical events.¹
- Use of LDL-lowering therapies is a core strategy in managing CVD risk.¹ Once therapy is initiated, LDL values are monitored to assess response to therapy and guide management decisions.
- Traditional low density lipoprotein-cholesterol (LDL-C) – calculated or direct - is an estimate of LDL quantity based on the amount of cholesterol contained in the LDL particles.¹ However, the amount of cholesterol per particle varies – particularly in patients with type II diabetes, in statin-treated patients, and those with the cardiometabolic risk (CMR) factors. LDL-C may be an unreliable measure of LDL quantity for these at-risk patients in a management setting.^{2,3}
- LDL particle (LDL-P) can be measured by nuclear magnetic resonance (NMR) or estimated by apolipoprotein B (Apo B). Neither NMR nor Apo B quantifies LDL-P in a manner that depends on the amount of cholesterol contained inside the LDL-P.
- LabCorp’s NMR LipoProfile test or Lipid Cascade options may help inform patient management in these at-risk populations.
- Each Lipid Cascade option begins with a traditional lipid panel. If the patient’s LDL-C value is < 130 mg/dL⁴, the traditional lipid panel reflexes to LDL-P measurement by NMR or estimation by Apo B, depending upon which Lipid Cascade option has been ordered.

AVAILABLE TESTS

Other

503935	Apo E Genotyping: Cardiovascular Risk
511238	Methylenetetrahydrofolate Reductase (MTHFR)
335884	Metabolic Syndrome Profile
004259	Thyroid-stimulating Hormone (TSH)
500140	Heart Disease and Stroke Risk Profile

Ambulatory ECG Monitoring Services

119530	Mobile Cardiovascular Telemetry (MCT)
999706	ECG Tracing and Computer Analysis
019372	Blood Pressure Monitoring
019380	Blood Pressure Unit—One-time Use and Analysis
009274	Holter Analysis Only
009324	Holter Recorder and Disposable Supplies - One-time Use and Analysis
019323	Holter Hook-up/Disconnect by LabCorp
019331	Holter Cardiologist Overread
119503	Patient-activated Event Monitoring (PAEM), Presymptom Cardiology Overread
119511	Patient-activated Event Monitoring (PAEM), Hook-up/Disconnect by LabCorp
119420	Patient-activated Event Monitoring (PAEM), Receipt of Transmissions
119180	ECG Computer Analysis Only
990333	ECG Cardiologist Overread Only, Adult

Genetic Testing for Inherited Structural and Electrical Conditions

252651	Atrial Septal Defect (ASD) With Atrioventricular Block (AVB): <i>NKX2.5</i> (Full Gene Sequencing)
252405	Atrial Septal Defect (ASD) With Atrioventricular Block (AVB): <i>NKX2.5</i> (Known Mutation)
252880	Early-onset Coronary Heart Disease/Familial Hypercholesterolemia: Three-gene Profile (<i>LDLR</i> , <i>APOB</i> , <i>PCSK9</i>)
451422	GeneSeq®: Cardio Familial Cardiomyopathy Profile
451412	GeneSeq®: Cardio Familial Arrhythmia Profile
451432	GeneSeq®: Cardio Familial Aortopathy Profile
451441	GeneSeq®: Cardio Noonan Syndrome and Related Conditions Profile
451402	GeneSeq®: Cardio Familial Congenital Heart Disease Profile
451416	GeneSeq®: Cardio Early-onset Coronary Artery Disease/Familial Hypercholesterolemia Profile
252419	Loeys-Dietz Syndrome (LDS): Two-gene Profile (<i>TGFBR1</i> , <i>TGFBR2</i>) (Full Gene Sequencing)
252406	Marfan Syndrome (MFS): <i>FBN1</i> (Full Gene Sequencing)
252654	Marfan Syndrome (MFS): <i>FBN1</i> (Known Mutation)
252409	Marfan Syndrome to Loeys-Dietz Syndrome Reflex Profile (<i>MFS</i> → <i>LDS</i>): <i>FBN1</i> → <i>TGFBR1</i> , <i>TGFBR2</i> (Full Gene Sequencing)
252399	Pulmonic Stenosis: <i>PTPN11</i> (Full Gene Sequencing)
252647	Pulmonic Stenosis: <i>PTPN11</i> (Known Mutation)
252422	Thoracic Aortic Aneurysms and Dissections (TAAD): Three-gene Profile (<i>FBN1</i> , <i>TGFBR1</i> , <i>TGFBR2</i>) (Full Gene Sequencing)

Acute Ischemic Markers

120816	Creatine Kinase (CK), MB
001362	Creatine Kinase (CK), Total
010405	Myoglobin
140150	Troponin T

AVAILABLE TESTS

Emerging Risk Factors & Inflammatory Markers

500140	Heart Disease and Stroke Risk Profile
120766	C-Reactive Protein (CRP), High Sensitivity (Cardiovascular Risk Assessment)
001610	Fibrinogen Activity
117052	Fibrinogen Antigen
706994	Homocyst(e)ine, Plasma
140916	Interleukin-6
123240	Lipoprotein-associated Phospholipase A2
146787	Plasminogen Activator Inhibitor I (PAI-1) Activity
005215	Sedimentation Rate, Modified Westergren

Diabetes

004650	Adiponectin
160721	Antipancreatic Islet Cells
001818	Glucose, Plasma
101000	Gestational Glucose Tolerance Screening and Diagnostic Test (Two-hour, ADA 2011 Standards)
143008	Glutamic Acid Decarboxylase (GAD) Autoantibody
001453	Hemoglobin (Hb) A _{1c}
102525	Hemoglobin (Hb) A _{1c} With eAG
141531	IA ₂ Autoantibodies (Endocrine Sciences)

Heart Failure

143000	NT-proBNP
004110	Galectin-3
140080	Galectin-3 With B-type Natriuretic Peptide
142005	Galectin-3 With NT-proBNP

Clotting Risk Assessment

005207	Partial Thromboplastin Time (PTT), Activated
020321	Prothrombin Time (PT) and Partial Thromboplastin Time (PTT)
512103	Thrombotic Risk Profile, DNA Analysis

Genetic Assessment

511710	Clopidogrel CYP2C19 Genotyping
511460	Warfarin (P450 2C9 and VKORC1)

Therapy Monitoring

005199	Prothrombin Time (PT)
485199	Prothrombin Time (PT) (Serial Monitor)
007385	Digoxin
706705	Amiodarone
085662	Flecainide, Serum or Plasma
007831	Quinidine, Serum or Plasma
007864	Disopyramide, Serum or Plasma

COMPLETING THE CONTINUUM OF CARDIOVASCULAR CARE

References

1. Toth, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*, Volume 235, Issue 2, August 2014. Pages 585–591.
2. Brunzell, JD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk. *Diabetes Care*, Vol. 31, No. 4, Apr 2008. Pages 811-822.
3. AACE Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. *Endocrine Practice*, Vol. 19 (Suppl 2), May/June 2013. Pages 1-48.
4. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program (NCEP) Expert Panel. NIH Publication No. 01-3670, May 2001.

For the most current information regarding test options, including specimen requirements and CPT codes, please consult the online Test Menu at www.LabCorp.com.



www.LabCorp.com